OncoKB New Data Release - May 20, 2025
13 views
Skip to first unread message
Contact OncoKB
May 20, 2025, 12:28:59 PMMay 20
to oncok...@googlegroups.com
Data Release v4.29
May 20, 2025
What's New
Updated Therapeutic Implications:
Promotion of tumor type-specific level of evidence for an alteration
Level 1: KRAS Oncogenic Mutations in low-grade serous ovarian cancer promoted from Level 4 to Level 1 based on FDA approval of Avutometinib + Defactinib for patients with KRAS mutant low-grade serous ovarian cancer (Abstract: Grisham et al. Abstract #814605, 2025 SGO Annual Meeting on Women’s Cancer)
- Level 4 sensitivity-associated evidence currently in OncoKB™ for KRAS Oncogenic Mutations in low-grade serous ovarian cancer: Binimetinib, Cobimetinib, Trametinib
Gene Curation:
Addition of 4 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
The OncoKB Team
Reply all
Reply to author
Forward
0 new messages